The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a greater substantial decrease in body size and enhance metabolic markers, particularly … Read More